Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloperidol versus placebo for schizophrenia.

C B Joy1, C E Adams, S M Lawrie

  • 1Cochrane Schizophrenia Group, Summertown Pavillion, Middle Way, Oxford, UK, OX2 7LG. claire@spoonbed.freeserve.co.uk

The Cochrane Database of Systematic Reviews
|June 19, 2001
PubMed
Summary

Haloperidol effectively manages schizophrenia symptoms, showing significant improvement compared to placebo. However, it carries a high risk of movement disorders like parkinsonism and dystonia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

White matter, cognition and psychotic-like experiences in UK Biobank.

Psychological medicine·2023
Same author

Experience of clinical services shapes attitudes to mental health data sharing: findings from a UK-wide survey.

BMC public health·2022
Same author

Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank.

Translational psychiatry·2020
Same author

Methylation of glucocorticoid receptor (NR3C1), BDNF and oxytocin receptor genes in association with childhood maltreatment in schizophrenia and schizoaffective disorder.

Schizophrenia research·2019
Same author

The role of neuroticism in self-harm and suicidal ideation: results from two UK population-based cohorts.

Social psychiatry and psychiatric epidemiology·2019
Same author

Tracking Staphylococcus aureus in the intensive care unit using whole-genome sequencing.

The Journal of hospital infection·2019

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Haloperidol, initially developed for analgesia, was later recognized for its antipsychotic properties.
  • It effectively addresses symptoms such as hallucinations, delusions, and agitation.

Purpose of the Study:

  • To assess the clinical efficacy of haloperidol in treating schizophrenia and similar serious mental illnesses.
  • Comparison was made against a placebo in randomized controlled trials.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through extensive electronic database searches.
  • Data from 20 RCTs involving patients with schizophrenia were analyzed on an intention-to-treat basis.
  • Key outcomes included clinical response, relapse rates, and adverse effects, with statistical analysis using relative risk and weighted mean differences.

Related Experiment Videos

Main Results:

  • Haloperidol demonstrated significant improvement in schizophrenia symptoms within the first six weeks of treatment compared to placebo (NNT=3).
  • Further analysis across 6-24 weeks also favored haloperidol, though potential overestimation exists due to unidentifiable small negative studies.
  • A notable finding was the high incidence of adverse effects, including acute dystonia, akathisia, and parkinsonism.

Conclusions:

  • Haloperidol is an effective antipsychotic but is associated with a substantial risk of movement disorders.
  • Its use is justified when no alternative treatments are available for severe schizophrenia.
  • Alternative antipsychotics with a lower risk of extrapyramidal side effects may be preferable when a choice exists.